UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

~~Pursuant to~~PURSUANT ~~Section~~TO SECTION 13 orOR 15(d) of ~~the~~OF ~~Securities~~THE ~~Exchange~~SECURITIES ~~Act~~EXCHANGE ofACT OF 1934

Date of Report (Date of ~~Earliest~~earliest ~~Event~~event ~~Reported~~reported): ~~August~~ 14September 16, 2025

~~CYTOSORBENTS~~Cytosorbents ~~CORPORATION~~Corp

(Exact name of registrant as specified in its charter)

Delaware		001-36792		98-0373793
(State or other jurisdiction of incorporation)		(Commission File Number)		(~~I.R.S.~~IRS Employer Identification No.)

305 College Road East Princeton, New Jersey	08540
305 COLLEGE ROAD EAST PRINCETON, New Jersey		08540
(Address of principal executive offices)	~~(Zip Code)~~	(Zip code)

Registrant’'s telephone number, including area code: (~~732~~973) 329-8885

Not Applicable ~~(Former name or former address, if changed since last report.)~~

(Former Name or Former Address, if Changed Since Last Report)

Securities registered pursuant to Section 12(b) of the Securities Exchange Act of 1934:

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value		NASDAQ

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

¨☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities ~~registered~~Act ~~pursuant~~of to1933 ~~Section 12~~(b§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter):

Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, $0.001 par value	CTSO	The Nasdaq Stock Market LLC (Nasdaq Capital Market)

Emerging growth company ☐

~~Indicate~~If an emerging growth company, indicate by check mark ~~whether~~if the registrant ishas anelected ~~emerging~~not ~~growth~~to ~~company~~use asthe ~~defined~~extended intransition ~~Rule~~period ~~405~~for ofcomplying ~~the~~with ~~Securities~~any ~~Act~~new ofor ~~1933~~revised ~~(§230.405 of~~financial ~~this~~accounting ~~chapter)~~standards provided orpursuant ~~Rule~~to ~~12b-2~~Section 13(a) of the ~~Securities~~ Exchange Act ~~of 1934 (§240~~.~~12b-2~~ ~~of this chapter).~~☐

~~Emerging~~Item ~~Growth~~7.01 ~~Company~~Regulation ¨FD Disclosure.

IfOn anSeptember ~~emerging~~16, ~~growth company~~2025, ~~indicate~~CytoSorbents byCorporation ~~check mark if~~ (the ~~registrant~~“Company”) ~~has~~issued ~~elected~~a ~~not~~press torelease ~~use~~providing ~~the~~a ~~extended~~regulatory ~~transition~~update ~~period~~on ~~for complying with any new or revised financial accounting~~DrugSorbTM-ATR. A ~~standards~~ copy ~~provided~~of ~~pursuant~~the topress ~~Section~~release ~~13(a)~~is offurnished ~~the~~herewith ~~Exchange~~as ~~Act.~~Exhibit ¨99.1.*

Item 8.01 ~~Results~~Other ~~of Operation and Financial Condition~~Events.

OnThe ~~August~~information ~~20,~~set ~~2025, CytoSorbents~~forth ~~Corporation~~under ~~(the~~ “~~Company”)~~Item ~~issued a press release announcing the outcome of its appeal to the U~~7.S.01 ~~Food and~~Regulation ~~Drug~~FD ~~Administration (the “FDA~~Disclosure”) ~~regarding the FDA’s earlier denial~~ of ~~the~~this ~~Company’s~~Current DeReport ~~Novo~~on ~~Market Authorization~~Form ~~request for DrugSorbTM~~8-~~ATR.~~K Ais ~~copy~~incorporated ofinto ~~the~~this ~~press~~Item ~~release~~8.01 isby ~~furnished herewith as Exhibit 99~~reference.1.

Item 9.01 Exhibits.

(d) Exhibits

Exhibit No.	Description
99.1	Press Release of the Company, dated ~~August~~September 2016, 2025
104	Cover Page Interactive Data File (embedded with the Inline XBRL document)

* The information in Item 7.01 of this Form 8-K shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”) or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933 or the Exchange Act, except as expressly set forth by specific reference in such a filing.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Dated: August 20, 2025	CYTOSORBENTS CORPORATION
Dated: September 16, 2025	CYTOSORBENTS CORPORATION
	By:	/s/ Dr. Phillip P. Chan
	Name:	Dr. Phillip P. Chan
	Title:	Chief Executive Officer

Filing Compare · Cytosorbents Corp